Evidence map›Paper›PMID 35960412›Full record

ArticleMolecular biology reports2022

Matrix metalloproteinase 3 and 9 as genetic biomarkers for the occurrence of cardiovascular complications in coronary artery disease: a prospective cohort study.

Imen Guizani, Wiem Zidi, Yosra Zayani, Fourti Nesrine, Hayet Douik, Haifa Sanhaji, Mohamed Sami Mourali, Moncef Feki, Monia Allal-Elasmi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Imen GuizaniLR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Wiem ZidiLR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Yosra ZayaniLR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Fourti NesrineLR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Hayet DouikLR99ES10 Human Genetics Laboratory, Faculty of Medicine of Tunis, University of Tunis El Manar, Tunis, Tunisia.
Haifa SanhajiLR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Mohamed Sami MouraliCardiology Department, CHU la Rabta, 1007, Jebbari Tunis, Tunisia.
Moncef FekiLR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
Monia Allal-ElasmiLR99ES11, Department of Biochemistry, La Rabta Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia. monia_elasmi@yahoo.fr.
Tunis El Manar University · TNHôpital La Rabta · TNFaculté de médecine de Tunis

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMatrix metalloproteinases (MMPs) are widely expressed in atherosclerosis lesions. The disequilibrium of MMPs driving to an overexpression or a lack of its level can be influenced by genetic variations. MMP-3 and MMP-9 may be affected by specific polymorphisms like - 1612 5 A/6A and the - 1562 C/T respectively. We aim in the present study to investigate prospectively the association between the - 1612 5 A/6A MMP-3 and - 1562 C/T MMP-9 polymorphisms and clinical outcomes in patients with coronary artery disease (CAD). This study is elaborated to reveal whether one of these polymorphisms is a probable predictor of cardiovascular complications in this CAD cohort. METHODS AND

resultsA total of 168 patients with CAD were prospectively followed up over a period of 5 years. Genotypes for the MMP-3 (-1612 5 A/6A) and MMP-9 (-1562 C/T) polymorphisms were performed using PCR-RFLP. Their levels were measured by ELISA in Sandwich test during the follow-up period, 39 cardiovascular outcomes occurred with 21 repeat targets for revascularization, 3 patients with Myocardial infarction, 8 for heart failure, 5 for Stroke and 2 for cardiovascular mortality. The MMP-3 5 A/6A polymorphism was related to the disease on the contrary of the MMP-9 -1562 C/T. Patients carrying the 5 A allele had a higher level of MMP-3 level and those who carried the 6 A allele had lower level (p = 0.04). After applied multivariable Cox-hazard models we revealed that the 6 A allele is independently associated to the disease complication. Kaplan-Meier survival test revealed that individuals having the 6 A allele had a lower survival rate than those with the 5 A allele (p = 0.04).

conclusionOur study suggests the disruption of the MMP-3 level may be due to the existence of the polymorphism - 1612 residing in its promoter region. MMP-3 can be considered as a marker of diagnosis and prediction in cardiovascular events.

Indexed as

Coronary Artery DiseaseMatrix Metalloproteinase 3BiomarkersGene FrequencyGenetic MarkersGenotypeHumansMatrix Metalloproteinase 9Prospective StudiesBiomarkersGenetic MarkersMatrix Metalloproteinase 3Matrix Metalloproteinase 9MMP3 protein, humanMMP9 protein, humanCardiovascular outcomesCoronary artery diseaseGenotypingMatrix metalloproteinases

Identifiers

PMID35960412
OpenAlexW4291144371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.